

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

11 Jul 2026

### Efficacy of Botulinum Toxin A Injection for Raynaud's Phenomenon and digital ulcers in patients with systemic sclerosis (scleroderma)

#### Protocol summary

##### Study aim

The effect of local botulinum toxin A injection on the improvement of symptoms of Raynaud's phenomenon and digital ulcers in systemic sclerosis

##### Design

Thirty patients will be included in the study. Non-dominant hands of patients will be used as intervention group and the dominant hands of patients as control group.

##### Settings and conduct

Before the intervention, patients' demographic information and the results of physical examinations will be recorded. Then Quick DASH, pain score (VAS) and Raynaud's condition score (RCS) questionnaires will be completed. Then, 50 units of botulinum toxin will be mixed with 2.5 cc of normal saline. The injection sites are: second-fourth interdigital webs (each one 10 units), base of thumb (10 units), second and fifth fingers (each 5 units). In the other hand, only normal saline will be injected in the same way. At end of months 1 and 4, patients will be reassessed.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: scleroderma diagnosis based on the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), age > 18 years, bilateral Raynaud's phenomenon with an intensity of greater than 50 according to the Raynaud's condition score (RCS), pain intensity greater than 5 based on visual analog scale (VAS), dysfunction of the arm, shoulder and hand more than 50 according to the Quick Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire. Exclusion criteria: Active infection in the hands, history of any botulinum toxin allergy, history of upper extremity vascular surgery, history of sympathectomy, pregnancy, breast feeding

##### Intervention groups

In the non-dominant hand, botulinum toxin A and into the dominant hand of each patient (as control), normal saline will be injected.

#### Main outcome variables

Symptoms of Raynaud's phenomenon; pain intensity; dysfunction of the arm, shoulder and hand

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20081202001479N7**

Registration date: **2018-12-29, 1397/10/08**

Registration timing: **prospective**

Last update: **2018-12-29, 1397/10/08**

Update count: **0**

##### Registration date

2018-12-29, 1397/10/08

##### Registrant information

##### Name

Mohammadhassan Jokar

##### Name of organization / entity

Mashhad University of Medical Science

##### Country

Iran (Islamic Republic of)

##### Phone

+98 51 1859 8818

##### Email address

jokarmh@mums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-01-10, 1397/10/20

##### Expected recruitment end date

2019-04-09, 1398/01/20

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Efficacy of Botulinum Toxin A Injection for Raynaud's Phenomenon and digital ulcers in patients with systemic sclerosis (scleroderma)

**Public title**

Botox in the treatment of Raynaud's phenomenon in scleroderma

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Scleroderma diagnosis based on the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) criteria age>18 years Bilateral Raynaud's phenomenon with an intensity greater than 50 according to the Raynaud's condition score (RCS) questionnaire Dysfunction of the arm and shoulder and arm more than 50 according to the Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire Pain intensity greater than 5 based on visual analog scale (VAS)

**Exclusion criteria:**

Active infection in any of the hands History of any botulinum toxin allergy History of upper extremity vascular surgery History of sympathectomy Pregnancy Breast feeding

**Age**

From **18 years** old

**Gender**

Both

**Phase**

4

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **30**

More than 1 sample in each individual

Number of samples in each individual: **2**

In this study, we will inject botulinum toxin A into the non-dominant hands and normal saline (as placebo) into the dominant hands of patients.

**Randomization (investigator's opinion)**

Not randomized

**Randomization description****Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Mashhad University for Medical Science

**Street address**

Mashhad University for Medical Science, Daneshgah street

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

1394491388

**Approval date**

2018-10-31, 1397/08/09

**Ethics committee reference number**

IR.MUMS.MEDICAL.REC.1397.334

**Health conditions studied****1****Description of health condition studied**

systemic sclerosis (scleroderma)

**ICD-10 code**

M34

**ICD-10 code description**

Systemic sclerosis [scleroderma]

**Primary outcomes****1****Description**

Raynaud's phenomenon symptoms

**Timepoint**

At the beginning of study and end of months 1 and 4

**Method of measurement**

Raynaud's phenomenon condition score Questionnaire

**Secondary outcomes****1****Description**

Ulcers of fingers

**Timepoint**

At the beginning and end of months 1 and 4

**Method of measurement**

Counting the number of ulcers and measuring the diameter of the ulcers

**2****Description**

Disabilities of the Arm, Shoulder and Hand

**Timepoint**

At the beginning of study and end of months 1 and 4

#### **Method of measurement**

Disabilities of the Arm, Shoulder and Hand  
Score(QuickDash)

### **Intervention groups**

#### **1**

##### **Description**

Control group: Dominant hands of the patients. Normal saline (total volume 2.5 cc) with insulin syringe will be injected into the following sites: second-forth interdigital webs, base of thumb, second and fifth fingers. Injection will only be done once.

##### **Category**

Placebo

#### **2**

##### **Description**

Intervention group: Non-dominant hands of patients. Fifty units of botulinum toxin (DYSPOUR®, IPSEN, UK) will be mixed with 2.5 cc of normal saline. The injection sites are: second-forth interdigital webs (each one 10 units), base of thumb (10 units), second and fifth fingers (each 5 units). Injection will only be done once.

##### **Category**

Treatment - Drugs

### **Recruitment centers**

#### **1**

##### **Recruitment center**

###### **Name of recruitment center**

Imam Reza Hospital, Mashhad

###### **Full name of responsible person**

Dr Mohammadhassan Jokar

###### **Street address**

Chamran street

###### **City**

Mashhad

###### **Province**

Razavi Khorasan

###### **Postal code**

9137913316

###### **Phone**

+98 51 3859 8818

###### **Email**

jokarmh@mums.ac.ir

### **Sponsors / Funding sources**

#### **1**

##### **Sponsor**

###### **Name of organization / entity**

Mashhad University of Medical Sciences

###### **Full name of responsible person**

Mohsen Tafaghodi

###### **Street address**

Daneshgah street, Vice-Chancellor for Research of  
Mashhad University of Medical Sciences

###### **City**

Mashhad

###### **Province**

Razavi Khorasan

###### **Postal code**

1394491388

###### **Phone**

+98 51 3841 2081

###### **Email**

Tafaghodim@mums.ac.ir

##### **Grant name**

Grant of Research Project of Vice-Chancellor for Research  
of Mashhad University of Medical Sciences

##### **Grant code / Reference number**

961794

##### **Is the source of funding the same sponsor organization/entity?**

No

##### **Title of funding source**

Mashhad University of Medical Sciences

##### **Proportion provided by this source**

100

##### **Public or private sector**

Public

##### **Domestic or foreign origin**

Domestic

##### **Category of foreign source of funding**

*empty*

##### **Country of origin**

##### **Type of organization providing the funding**

Academic

### **Person responsible for general inquiries**

##### **Contact**

###### **Name of organization / entity**

Mashhad University of Medical Sciences

###### **Full name of responsible person**

Mohammadhassan Jokar

###### **Position**

Associated professor

###### **Latest degree**

Subspecialist

###### **Other areas of specialty/work**

Internal Medicine

###### **Street address**

Chamran street

###### **City**

Mashhad

###### **Province**

Razavi Khorasan

###### **Postal code**

9137913316

###### **Phone**

+98 51 3859 8818

###### **Email**

jokarmh@mums.ac.ir

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Mashhad University of Medical Sciences

**Full name of responsible person**

Mohammad Hassan Jokar

**Position**

Associated professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Internal Medicine

**Street address**

Chamran St. Imam Reza Hospital

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9137913316

**Phone**

+98 51 3859 8818

**Email**

jokarmh@mums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

Mashhad University of Medical Sciences

**Full name of responsible person**

Mohammad Hassan Jokar

**Position**

MD, Rheumatologist, Associated Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Internal Medicine

**Street address**

Internal medicine ward, Imam Reza Hospital,  
Chamran street

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9177899191

**Phone**

+98 51 3859 8818

**Fax**

+98 51 3859 8818

**Email**

jokarmh@mums.ac.ir

**Web page address**

<http://my.mums.ac.ir/default.aspx>

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no further information

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available